(Q45742384)

15 December 2017

title

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine (English)

1 reference

15 December 2017

main subject

etravirine

1 reference

ChEBI release 2020-05-28

1 reference

Vi T Do

1

1 reference

15 December 2017

Robert T Higginson

series ordinal

2

1 reference

15 December 2017

Patricia Pecora Fulco

series ordinal

3

1 reference

15 December 2017

publication date

1 November 2011

1 reference

15 December 2017

American Journal of Health-System Pharmacy

published in

1 reference

15 December 2017

volume

68

1 reference

15 December 2017

issue

21

1 reference

15 December 2017

page(s)

2049-2054

1 reference

15 December 2017

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Raltegravir with optimized background therapy for resistant HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Effects of omeprazole on plasma levels of raltegravir

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Pharmacogenetics of phase I and phase II drug metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

Integrase inhibitors: a novel class of antiretroviral agents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110083

31 March 2020

Identifiers

DOI

10.2146/AJHP110083

1 reference

15 December 2017

1 reference

15 December 2017